They were once the kings of computed tomography (CT) — 16-slice scanners that hinted at coronary CT angiography; 64 slicers that delivered it. Today they are entry level and mid-tier products: streamlined in function; optimized for dose; automated for efficiency; and reduced — dramatically — in price.

Beyond them at the high-end are premium scanners producing — even exceeding — 256 slices per rotation. Some can characterize tissue based on the atomic numbers of its elements, an extraordinary capability that puts CT on the cusp of molecular imaging.

Fetuses with enlarged ventricles — the fluid-filled cavities inside the brain — determined by magnetic resonance imaging (MRI) scans may be less likely to benefit from surgery in the womb to treat spina bifida, according to a National Institutes of Health-supported study.

Samsung has been awarded a group purchasing agreement for general radiography, computed tomography (CT) and ultrasound with Premier Inc., a leading healthcare improvement company, effective Oct. 1, 2015. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for digital radiography, CT, and ultrasound products.

IBA (Ion Beam Applications SA) announced that it has signed a contract with the company INVAP for the installation of a proton therapy center at the Instituto de Oncologia Angel Roffo hospital in Buenos Aires, Argentina.

Visit www.itnonline.com/events for a comprehensive list of upcoming radiology events.

Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

Shimadzu Medical Systems USA announced the first Sonialvision G4 universal radiographic fluoroscopy (R/F) system installed in Canada.

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. In the study, the imaging agent — Ga-68 prostate-specific membrane antigen (Ga-68 PSMA) — used with positron emission tomography and computed tomography (PET/CT), changed management in 44 percent more cases than another widely used agent.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now